Xeris Biopharma officer sells 90,000 shares
Xeris Biopharma Holdings officer Kevin McCulloch reported an open-market sale of 90,000 shares of common stock at a weighted average price of $8.0279 per share on July 1, 2026.
Rhea-AI Filing Summary
Xeris Biopharma Holdings officer Kevin McCulloch reported an open-market sale of 90,000 shares of common stock at a weighted average price of $8.0279 per share on July 1, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025.
After the transaction, McCulloch directly owns 1,691,126 shares of Xeris Biopharma common stock. An additional 25,000 shares are held indirectly by his spouse, including 3,401 shares acquired on June 30, 2026 under the company’s 2018 Employee Stock Purchase Plan, with beneficial ownership of those indirect shares disclaimed except for any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 90,000 shares
Net Sell
2 txns
Insider
McCulloch Kevin
Role
See Remarks
Sold
90,000 shs ($723K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 90,000 | $8.0279 | $723K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 1,691,126 shares (Direct);
Common Stock — 25,000 shares (Indirect, By Spouse)
Footnotes (4)
- F1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person as of September 4, 2025.
- F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.000 to $8.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. Includes 3,401 shares acquired on June 30, 2026 under the issuer's 2018 Employee Stock Purchase Plan, as amended.
- F4. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Key Figures
Shares sold: 90,000 shares
Weighted average sale price: $8.0279 per share
Direct holdings after sale: 1,691,126 shares
+2 more
5 metrics
Shares sold
90,000 shares
Open-market sale on July 1, 2026
Weighted average sale price
$8.0279 per share
Common stock sale on July 1, 2026
Direct holdings after sale
1,691,126 shares
Common stock owned directly after transactions
Indirect spouse holdings
25,000 shares
Common stock held by spouse, indirect ownership
ESPP shares acquired
3,401 shares
Acquired June 30, 2026 under 2018 Employee Stock Purchase Plan
Key Terms
Rule 10b5-1 trading plan, weighted average price, 2018 Employee Stock Purchase Plan, beneficial ownership, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person as of September 4, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.000 to $8.10, inclusive."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
2018 Employee Stock Purchase Plan financial
"Includes 3,401 shares acquired on June 30, 2026 under the issuer's 2018 Employee Stock Purchase Plan, as amended."
beneficial ownership regulatory
"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
FAQ
What insider transaction did Xeris Biopharma (XERS) report for Kevin McCulloch?
Xeris Biopharma reported that officer Kevin McCulloch sold 90,000 shares of common stock. The sale occurred on July 1, 2026 at a weighted average price of $8.0279 per share through multiple transactions within a disclosed price range.
AI-generated analysis. How Rhea-AI works. Not financial advice.
